Top Markets
Coin of the day
Clovis Oncology, Inc. Clovis Oncology, Inc.

Clovis Oncology, Inc.

C6O
Ранг среди акций #30761
Clovis Oncology, Inc. is a biopharmaceutical company focused on the discovery,... Clovis Oncology, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of anti-cancer agents, serving markets in the United States, Europe, and globally. Its flagship commercial product in the U.S. is Rubraca (rucaparib), an oral small molecule designed to inhibit poly ADP-ribose polymerase. This treatment is indicated for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, Rubraca is offered for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. The company's pipeline includes lucitanib, an investigational angiogenesis inhibitor that targets vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/ß), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3). Also under development is FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent that specifically acts upon fibroblast activation protein. Rubraca is distributed through a select network of specialty distributors and pharmacies, which then supply the medication to patients and healthcare providers. Clovis Oncology has established strategic collaborations, including license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH. The company also maintains a clinical collaboration with Bristol Myers Squibb Company and a partnership with Foundation Medicine, Inc. Founded in 2009, Clovis Oncology, Inc. is headquartered in Boulder, Colorado.
Цена акции
$0.10794012
Последняя синхронизация: 2022-12-15
Рыночная капитализация
$15.65M
Изменение (1 день)
-17.06%
Изменение (1 год)
0.00%
Страна
US
Торговля Clovis Oncology, Inc. (C6O)

Категория

EPS для Clovis Oncology, Inc. (C6O)
EPS по состоянию на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций Clovis Oncology, Inc., текущий EPS компании (TTM) составляет 0. В конце 2026 EPS компании составлял 0, равна показателю 2026 года, равному 0.
История EPS компании Clovis Oncology, Inc. с 2026 по 2026
EPS на конец каждого года
Год EPS Изменить
Недостаточно данных для указанных дат.
EPS для аналогичных компаний или конкурентов
Компания EPS Разница в EPS Страна
$17.32 -
US
$27.74 -
NL
$2.98 -
AU
- -
CH
$13.70 -
BE